Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brickell partners retinoid compound BBI3000 with Merz

Executive Summary

Dermatology start-up Brickell Biotech Inc. licensed Merz North America Inc. (skin and CNS diseases) exclusive North American rights to its preclinical topical retinoid X agonist BBI3000 for acne and psoriasis, two conditions known to respond to retinoid compounds.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register